Apolipoprotein AIV
Product Sizes
0.05 mg
16-16-120104-0.05MG
About this Product
- SKU:
- 16-16-120104
- Additional Names:
- ApoAIV|Cardiovascular Research, Diabetes Research, In Vitro Diagnostic
- Buffer:
- Frozen in 1 mM NH4HCO3, pH 8.2
- CE/IVD:
- RUO
- Extra Details:
- Apolipoprotein A-IV (ApoA-IV), a glycoprotein synthesized predominantly in the small intestine during fat absorption, is a structural component of HDL and chylomicrons. Its four-helix bundle architecture facilitates lipid emulsification and interaction with apolipoprotein B (apoB) to promote chylomicron assembly and secretion. Postprandially, ApoA-IV dissociates from chylomicrons into the lipoprotein-free plasma fraction, where it activates lecithin-cholesterol acyltransferase (LCAT) and enhances lipoprotein lipase (LPL) activity via apoC-II, critical for triglyceride-rich lipoprotein catabolism. ApoA-IV exhibits protective roles against cardiovascular disease (CVD) by inhibiting vascular inflammation through NF-K KappaB suppression and upregulating DHCR24, an anti-inflammatory enzyme. Genetic variants like APOA4 S347 correlate with elevated coronary heart disease (CHD) risk and reduced plasma ApoA-IV levels. In metabolic regulation, ApoA-IV improves insulin sensitivity by stimulating GLUT4 translocation in adipocytes via PI3K-Akt pathways and enhances glucose-stimulated insulin secretion, with deficiencies linked to glucose intolerance. Chronic high-fat diets blunt its satiety signaling, contributing to obesity, while Roux-en-Y gastric bypass increases ApoA-IV, correlating with weight loss and improved glucose control56. Clinically, ApoA-IV serves as a biomarker for CHD risk and diabetes progression. Therapeutic strategies targeting its anti-inflammatory, insulinotropic, and lipid-modulating properties show promise for metabolic and cardiovascular disorders.
- Formulation:
- Frozen in 1 mM NH4HCO3, pH 8.2
- Molecular Weight:
- 46,000 Da
- Physical State:
- Lyophilized
- Purity:
- ≥85%
- Purification:
- Liquid Chromatography Methods
- Shipping Conditions:
- Dry Ice
- Source:
- Source human plasma non-reactive for HBsAG, anti-HCV, anti-HBc, and negative for anti-HIV 1 & 2 by FDA approved tests.
- Storage Conditions:
- Please refer to datasheet
- Supplier:
- Athens Research & Technology Inc.
- Type:
- Proteins, Peptides, Small Molecules & Other Biomolecules: Native
